68Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer.
Daniela A FerraroUrs J MuehlematterHelena I Garcia SchülerNiels J RuppMartin HuellnerMichael MesserliJan Hendrik RüschoffEdwin E G W Ter VoertThomas HermannsIrene Andrea BurgerPublished in: European journal of nuclear medicine and molecular imaging (2019)
Our model combining PSA, Gleason score and visual lymph node analysis on 68Ga-PSMA-11 PET with PSMAtotal of the primary tumour showed a tendency to improve patient selection for ePLND over the currently used clinical nomograms. Although this result has to be validated, 68Ga-PSMA-11 PET showed the potential to reduce unnecessary surgical procedures in patients with intermediate- or high-risk prostate cancer.